^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Rectal Cancer
    Drug:Lonsurf (trifluridine/tipiracil) (Thymidine phosphorylase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/20/2020
    Excerpt:
    Rectal cancer:.Subsequent therapy…Trifluridine + tipiracil modified with the addition of ± bevacizumab